To explore the risk of uncontrolled chemotherapy-induced nausea and vomiting (CINV) associated with palonosetron (a 5-hydroxy tryptamine3-receptor antagonist [5-HT3-RA]) initiation versus other 5-HT3-RAs among patients with cancer on chemotherapy (CT) treatment in a hospital outpatient setting. METHODS: Patients with a cancer diagnosis initiating CT and anti-emetic prophylaxis with palonosetron (Group 1) and other 5-HT3-RAs (Group 2) for the fi rst time (index date) between April 1, 2007 and March 31, 2009 were identifi ed from the Premier Perspective (TM) Database. Inclusion criteria were patients aged ≥18 years, no evidence of nausea and vomiting or a hospital charge for a CT or anti-emetic medication in the 6-month pre-index date period, and 36 consecutive months of hospital data submission. Patients were followed through eight CT cycles or 6 months post-index date, whichever occurred fi rst. a negative binomial distribution-generalized linear multivariate regression model estimating the number of CINV events on CT-matched groups in the follow-up period was developed after adjusting for several demographic and clinical variables. RESULTS: Of 9144 identifi ed patients, 1775 initiated palonosetron (Group 1; 19.4%). Group 1 patients were signifi cantly younger (61.2 [SD: 13.0] vs. 62.8 [13.1] years; P < 0.0001), comprised more females (52.5% vs. 41.1%; P < 0.0001), less Blacks (8.6% vs. 13.2%; P < 0.0001), more highly emetogenic CT (43.3% vs. 28.5%; P < 0.0001), and more lung (26.1% vs. 22.4%; P < 0.0001) and breast cancer patients (19.3% vs. 15.3%; P < 0.0001). In the follow-up period, the number of unadjusted CINV events was statistically lower for Group 1 (8336 vs. 9400; P = 0.0007) patients. The regression model predicted a 13.7% decrease in the total CINV events per patient per cycle for Group 1 patients versus Group 2 patients; P = 0.0006. CONCLUSIONS: In this retrospective hospital outpatient study, patients with cancer initiated on palonosetron were more likely to experience a signifi cantly lower rate of CINV events versus those initiating other 5-HT3-RAs. Patients aged ≥18 years, no evidence of nausea and vomiting or a hospital charge for a CT agent or antiemetic medication in the 6-month pre-index period, and 36 consecutive months of hospital data submission were included. Patients were followed through eight CT cycles or 6 months post-index date, whichever occurred fi rst. CT was categorized as highly emetogenic (HEC), moderately emetogenic (MEC), low emetogenic (LEC), or minimal emetogenic (MinEC) per National Comprehensive Cancer Network guidelines. a descriptive analysis of changes in CINV events (either a diagnosis of nausea and/or vomiting or evidence of CINV-related medications) per CT cycle per CT emetogenicity was performed in the follow-up period. RESULTS: The overall study population (N = 11,495) had an average age of 63.3 years (SD 13.4), was 50.7% female, and 86% white. Most common tumor types were lung (19.8%), breast (15.9%), and urinary tract (13.8%). Use of HEC (cycle 1: 26.0% vs. study end: 9.8%; P = < 0.0001) decreased over the follow-up period. Change in CINV events from cycle 1 to study end was statistically signifi cant for HEC (32.1% vs. 29.9%; P < 0.0001), MEC (38.4% vs. 39.9%; P < 0.0001), LEC (26.4% vs. 27.8%; P < 0.0001), and MinEC (3.2% vs. 2.4%; P < 0.0001). The % point change from cycle 1 to study end was also statistically signifi cant between groups (HEC [−2.2%] vs. MEC [+1.5%] vs. LEC [+1.4%] vs. MinEC [−0.8%]; P < 0.0001). CONCLUSIONS: In this retrospective hospital outpatient study, patients with cancer initiated on MEC and LEC experienced signifi cantly higher CINV events over time versus HEC-initiated patients.
PCN3

CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING EVENTS BY CHEMOTHERAPY EMETOGENICITY IN PATIENTS WITH CANCER TREATED IN A HOSPITAL OUTPATIENT SETTING
Craver C 1 , Gayle J 1 , Balu S 2 , Buchner D 2 1 Premier, Inc, Charlotte, NC, USA; 2 Eisai, Inc., Woodcliff Lake, NJ, USA OBJECTIVES: To characterize the changes in chemotherapy-induced nausea and vomiting (CINV) events by chemotherapy (CT) emetogenicity among patients with cancer initiating CT treatment in a hospital outpatient setting. METHODS: Patients with cancer initiating CT for the fi rst time (index date) between April 1, 2007 and March 31, 2009 were extracted from the Premier Perspective comparative database. Patients aged ≥18 years, no evidence of nausea and vomiting or a hospital charge for a CT agent or antiemetic medication in the 6-month pre-index period, and 36 consecutive months of hospital data submission were included. Patients were followed through eight CT cycles or 6 months post-index date, whichever occurred fi rst. CT was categorized as highly emetogenic (HEC), moderately emetogenic (MEC), low emetogenic (LEC), or minimal emetogenic (MinEC) per National Comprehensive Cancer Network guidelines. a descriptive analysis of changes in CINV events (either a diagnosis of nausea and/or vomiting or evidence of CINV-related medications) per CT cycle per CT emetogenicity was performed in the follow-up period. RESULTS: The overall study population (N = 11,495) had an average age of 63.3 years (SD 13.4), was 50.7% female, and 86% white. Most common tumor types were lung (19.8%), breast (15.9%), and urinary tract (13.8%). Use of HEC (cycle 1: 26.0% vs. study end: 9.8%; P = < 0.0001) decreased over the follow-up period. Change in CINV events from cycle 1 to study end was statistically signifi cant for HEC (32.1% vs. 29.9%; P < 0.0001), MEC (38.4% vs. 39.9%; P < 0.0001), LEC (26.4% vs. 27.8%; P < 0.0001), and MinEC (3.2% vs. 2.4%; P < 0.0001). The % point change from cycle 1 to study end was also statistically signifi cant between groups (HEC [−2.2%] vs. MEC [+1.5%] vs. LEC [+1.4%] vs. MinEC [−0.8%]; P < 0.0001). CONCLUSIONS: In this retrospective hospital outpatient study, patients with cancer initiated on MEC and LEC experienced signifi cantly higher CINV events over time versus HEC-initiated patients.
PCN4 LIKELIHOOD OF A SUBSEQUENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) EVENT IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY (MEC/HEC)
Feinberg B 1 , Gilmore J 1 , Haislip S 1 , Jackson J 2 , Jain G 2 , Balu S 3 , Buchner D 3 1 Georgia Cancer Specialists, Atlanta, GA, USA; 2 Xcenda, LLC., Palm Harbor, FL, USA; 3 Eisai, Inc., Woodcliff Lake, NJ, USA OBJECTIVES: CINV with MEC and HEC therapy is well studied, but the association of prior history of CINV with the future risk of CINV is not well quantifi ed. This study assessed the increased likelihood of a subsequent CINV following a fi rst administration CINV in patients on single-day MEC/HEC therapy. METHODS: A retrospective analysis was conducted utilizing Georgia Cancer Specialists electronic medical records database (October 2006 -August 2009 . Patients who received >1 single-day MEC/HEC administration with no chemotherapy 3 months prior were included. Patients who received multiday chemotherapy, started with low emetogenic chemotherapy, or had no dosing information were excluded. Two cohorts, a fi rst administration CINV (Group 1) and no fi rst administration CINV (Group 2), were created and followed for 6 months. a multivariate logistic regression assessed the likelihood of subsequent CINV during the 6-month follow-up, controlling for age, gender, Charlson comorbidity index, cancer type, gap between administrations, and chemotherapy emetogenicity. Sub-analyses were performed for patients initiated on MEC and HEC. RESULTS: A total of 3721 patients met inclusion criteria; 423 (11.37%) experienced a fi rst administration CINV. These patients were younger (56.6 vs. 59.4; P < 0.0001), had lower comorbidity index (2.1 vs. 2.2; P = 0.0154), and had more gaps between administrations (18.5 vs. 17.4; P = 0.0204). Unadjusted subsequent CINV rate was higher in the Group 1 cohort (52.3% vs. 24.2%; P < 0.0001). After controlling for covariates, Group 1 patients were 3.5 times more likely to have a subsequent CINV compared to Group 2 patients (odds ratio [OR]: 3.48 [95% CI: 2.81-4.30]; P < 0.0001). Sub-analyses by MEC/HEC supported overall analysis (HEC OR: 2.9 [95% CI: 2.1-3.9; P < 0.0001]) and (MEC OR: 4.1 [95% CI: 3.1-5.5; P < 0.0001]). CON-CLUSIONS: In this retrospective analysis, patients receiving single-day MEC/HEC who had a prior CINV were at increased risk of subsequent CINV. Further research on the clinical and economic impact of early and appropriate anti-emetic prophylaxis is required. (RR) and the correspondent 95% confi dence interval (CI). RESULTS: Six studies were included, comprising 2201 patients. PAL was compared to Ondansetron, Granisetron, and Dolasetron. Patients in PAL group had less nausea, both acute (RR = 0.86; CI 95% = 0.76 to 0.96; P = 0.007) and delayed (RR = 0.82; CI 95% = 0.75 to 0.89; P < 0.00001). They also had less acute vomiting (RR = 0.77; CI 95% = 0.67 to 0.88; P = 0.0001) and delayed vomiting (RR = 0.78; CI 95% = 0.70 to 0.86; P < 0.00001). There were no statistical differences in adverse events like headache (RR = 0.84; CI 95% = 0.61 to 1.17; P = 0.30), dizziness (RR = 0.40; CI 95% = 0.13 to 1.27; P = 0.12), constipation (RR = 1.29; CI 95% = 0.77 to 2.17; P = 0.33), or diarrhea (RR = 0.67; CI 95% = 0.24 to 1.85; P = 0.44). Patients receiving PAL presented less nausea and vomiting regardless of the use of corticosteroids. CONCLUSIONS: PAL was more effective than the other 5-HT3R in preventing acute and delayed CINV in patients receiving MoHE treatments, regardless of the use of concomitant corticosteroids.
PCN5 EFFICACY OF PALONOSETRON (PAL) COMPARED TO OTHER SEROTONIN INHIBITORS (5-HT3R) IN PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT: AN UPDATE OF THE PREVIOUSLY PUBLISHED SYSTEMATIC REVIEW AND META-ANALYSIS
PCN6 PRESERVED ANTITUMOR ACTIVITY AND REDUCED CARDIOTOXICITY OF FIRST-LINE PEGYLATED LIPOSOMAL DOXORUBICIN COMPARED WITH CONVENTIONAL DOXORUBICIN IN PATIENTS WITH METASTATIC BREAST CANCER
Mann K, Rana C, Wadhwa A Heron Health Private Ltd., Chandigarh, India OBJECTIVES: Doxorubicin is an anthracycline used in the treatment of breast cancer, but its use is limited by cumulative dose-dependent cardiotoxicity. Pegylated liposomal doxorubicin is a novel drug delivery system that alters biodistribution of doxorubicin resulting in reduced cardiotoxicity. Our aim is to compare the effi cacy and cardiotoxicity of pegylated liposomal doxorubicin and conventional doxorubicin in fi rst-line treatment of metastatic breast cancer (MBC). METHODS: The literature databases (Cochrane Library, EMBASE, and PUBMED) were searched from inception to May 2010. Randomized controlled trials assessing the effi cacy and cardiotoxicity of pegylated liposomal doxorubicin compared to conventional doxorubicin in fi rst-line treatment of MBC were included. Two reviewers independently selected trials, assessed quality, and extracted data, and a third reviewer resolved discrepancies. The fi xed effects meta-analysis was performed in STATA 9.0 using a standard meta-analysis approach. RESULTS: Two studies assessing pegylated liposomal doxorubicin with conventional doxorubicin for fi rst-line treatment of MBC met the study criteria. Overall survival (HR = 0.869 [95% CI; 0.720, 1.049]) and overall response rate (RR = 0.908 [95% CI; 0.725, 1.139]) were comparable between the two arms. Treatment with pegylated liposomal doxorubicin resulted in signifi cant reduction in cardiotoxicity as compared to conventional doxorubicin (RR = 0.312 [95% CI; 0.198, 0.490] ). The results of random effect analysis were similar (data not shown). CONCLUSIONS: Pegylated liposomal doxorubicin provides comparable antitumor activity in terms of effi cacy and is better tolerated as compared to conventional doxorubicin in the treatment of MBC. Thus, the liposomal drug delivery system can play a signifi cant role in the use of doxorubicin in MBC treatment which is otherwise limited by its cardiotoxicity and supports its use in fi rst-line treatment of MBC.
